Jyong Biotech Ltd. (NASDAQ:MENS – Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $38.87, but opened at $36.41. Jyong Biotech shares last traded at $37.91, with a volume of 1,969 shares.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jyong Biotech in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.
View Our Latest Report on MENS
Jyong Biotech Trading Up 3.6%
About Jyong Biotech
OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.
Further Reading
- Five stocks we like better than Jyong Biotech
- Using the MarketBeat Dividend Yield Calculator
- Monday.com Opens Generational Opportunity With Manic Sell-Off
- Stock Market Sectors: What Are They and How Many Are There?
- An Earnings Win With a Stock Slump: What’s Happening With D-Wave?
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- 3 Stocks Showing Relative Strength as Markets Pull Back
Receive News & Ratings for Jyong Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jyong Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
